Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
ALKEM
Mr. Sandeep Derjit Singh · Mumbai, India
₹5,672.50
▲+0.37%ALKEM's strong fundamentals, driven by growth in its specialty and generic segments, are reflected in its 14.60% YoY revenue growth and 17.56% ROE.
Exchange
NSI
Currency
INR
Day range
₹5,654.00 – ₹5,711.50
52-week range
₹4,738.50 – ₹5,933.50
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis80% confidence
ALKEM's current price of 5672.5 INR trades towards the upper end of its 1-year range and may warrant a reduction in valuation expectations.
4.4% below the 1-year high · trend down
Hedge-fund memo
Today
ALKEM's 0.37% gain today is a minor extension of its upward trend.
This week
The stock maintains its 52-week high and is trading near the top of its day range.
This month
ALKEM has had a relatively stable month, with the stock price oscillating within a relatively narrow range.
Bull thesis
Bear thesis
Hidden risks
Hidden opportunities
News & sentiment
Neutral
10 headlines · 8 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 2 of 4 recent quarters (EPS actual vs. consensus).
26.4989 vs 39.25
-32.49% surprise
56.8833 vs 57.97333
-1.88% surprise
63.99 vs 60.55
5.68% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| ALKEM | 678.23B | 29.43 | 17.56% | 11.42% | 14.60% |
| TORNTPHARM | 1.86T | 76.61 | 16.99% | 20.20% | 41.80% |
| IPCALAB | 450.20B | 39.52 | 13.22% |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 499sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Debt Levels
Mitigation: ALKEM's strong cash flows and efficient operations help mitigate the risks associated with its debt levels.
Generic Segment
Mitigation: ALKEM's diversification into specialty segments helps reduce its dependence on the generic segment.
Regulatory Headwinds
Mitigation: ALKEM's strong track record of compliance and adaptation to regulatory changes helps mitigate potential risks.
Business intelligence
Competitive moat
ALKEM's strong brand recognition, R&D capabilities, and economies of scale provide a durable competitive advantage in the generic and specialty segments.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Launch of new products in the specialty segment
Thesis builder
Bull case
ALKEM's continued growth in the specialty segment and increasing presence in global markets can drive its stock price upwards.
Base case
Strong fundamentals and industry trends support a long-term bullish stance.
Bear case
Decline in the generic segment's competitiveness or regulatory headwinds may negatively impact the company's growth prospects.
Time horizon
3-5 years
Est. CAGR
15-20%
Entry (qual.)
Investors should seek opportunities to enter the stock when it drops below a price band of 5000-5500 INR.
Exit (qual.)
Investors may look to exit the stock if it fails to maintain its revenue growth momentum or faces significant headwinds in its specialty segment.
Overall conviction 80%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how ALKEM fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain ALKEM for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Watch next
Investors should maintain their focus on the company's strategic initiatives to further enhance its market presence.
NTD News·22h ago·recalled medication nationwide
Law360·1d ago·AbbVie block attempt
Goodreturns·2d ago·unrelated earnings list
scanx.trade·2d ago·quarterly results scheduled
CXO Digitalpulse·2d ago·business promotion international
CNBC TV18·4d ago·unrelated index fund mention
CNBC TV18·4d ago·unrelated index fund mention
Samco·4d ago·pharma stock mention
scanx.trade·4d ago·executive resignation news
Business Today·6d ago·negative industry trend news
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
54.6226 vs 45.8
19.26% surprise
| 18.48% |
| 6.30% |
| ABBOTINDIA | 589.56B | 37.95 | 34.46% | 27.02% | 6.50% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹5,654.00
Resistance (day/52w high)
₹5,711.50
Volume
57,545
Trend
down
RSI (14)
52
MACD
bearish
MA cross
death
50-day MA
₹5,473.06
200-day MA
₹5,540.27
vs 200-DMA
2.4%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.